Trader consensus on Polymarket reflects a closely balanced 50.5% implied probability for "No" on Eli Lilly licensing Peptron's SmartDepot long-acting drug delivery platform by October 7, 2026, driven by the ongoing platform technology evaluation agreement—originally signed October 7, 2024, and extended in December 2025 for additional in-vivo studies—which shows smooth joint research progress but no full licensing commitment yet. Recent Eli Lilly M&A activity, including a 52 trillion won spree highlighted April 29 and partnerships like Camurus for competing long-acting tech, tempers optimism amid a pivot toward oral obesity drugs like orforglipron, while Korean investments and Tirzepatide API production hint at potential SmartDepot integration for monthly dosing. The evaluation deadline itself looms as the decisive catalyst, with any pre-October announcement able to swing odds sharply.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · ActualizadoNUEVO
NUEVO
7 oct 2026
NUEVO
NUEVO
7 oct 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Trader consensus on Polymarket reflects a closely balanced 50.5% implied probability for "No" on Eli Lilly licensing Peptron's SmartDepot long-acting drug delivery platform by October 7, 2026, driven by the ongoing platform technology evaluation agreement—originally signed October 7, 2024, and extended in December 2025 for additional in-vivo studies—which shows smooth joint research progress but no full licensing commitment yet. Recent Eli Lilly M&A activity, including a 52 trillion won spree highlighted April 29 and partnerships like Camurus for competing long-acting tech, tempers optimism amid a pivot toward oral obesity drugs like orforglipron, while Korean investments and Tirzepatide API production hint at potential SmartDepot integration for monthly dosing. The evaluation deadline itself looms as the decisive catalyst, with any pre-October announcement able to swing odds sharply.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Mercado abierto: May 5, 2026, 8:02 PM ET
Volumen
$2,232Fecha de finalización
7 oct 2026Mercado abierto
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Trader consensus on Polymarket reflects a closely balanced 50.5% implied probability for "No" on Eli Lilly licensing Peptron's SmartDepot long-acting drug delivery platform by October 7, 2026, driven by the ongoing platform technology evaluation agreement—originally signed October 7, 2024, and extended in December 2025 for additional in-vivo studies—which shows smooth joint research progress but no full licensing commitment yet. Recent Eli Lilly M&A activity, including a 52 trillion won spree highlighted April 29 and partnerships like Camurus for competing long-acting tech, tempers optimism amid a pivot toward oral obesity drugs like orforglipron, while Korean investments and Tirzepatide API production hint at potential SmartDepot integration for monthly dosing. The evaluation deadline itself looms as the decisive catalyst, with any pre-October announcement able to swing odds sharply.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volumen
$2,462Fecha de finalización
7 oct 2026Mercado abierto
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Trader consensus on Polymarket reflects a closely balanced 50.5% implied probability for "No" on Eli Lilly licensing Peptron's SmartDepot long-acting drug delivery platform by October 7, 2026, driven by the ongoing platform technology evaluation agreement—originally signed October 7, 2024, and extended in December 2025 for additional in-vivo studies—which shows smooth joint research progress but no full licensing commitment yet. Recent Eli Lilly M&A activity, including a 52 trillion won spree highlighted April 29 and partnerships like Camurus for competing long-acting tech, tempers optimism amid a pivot toward oral obesity drugs like orforglipron, while Korean investments and Tirzepatide API production hint at potential SmartDepot integration for monthly dosing. The evaluation deadline itself looms as the decisive catalyst, with any pre-October announcement able to swing odds sharply.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado
Cuidado con los enlaces externos.
Cuidado con los enlaces externos.
Preguntas frecuentes